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BACKGROUND:The cutoff of semi-quantitative immunochemical faecal occult blood tests (iFOBTs) influences colonoscopy referrals and
detection rates. We studied the performance of an iFOBT (OC-Sensor) in colorectal cancer (CRC) screening at different cutoffs.
METHODS: Dutch screening participants, 50–75 years of age, with average CRC risk and an iFOBT value X50ngml
 1 were offered
colonoscopy. The detection rate was the percentage of participants with CRC or advanced adenomas (X10mm, X20% villous,
high-grade dysplasia). The number needed to scope (NNTScope) was the number of colonoscopies to be carried out to find one
person with CRC or advanced adenomas.
RESULTS: iFOBT values X50ngml
 1 were detected in 526 of 6157 participants (8.5%) and 428 (81%) underwent colonoscopy. The
detection rate for advanced lesions (28 CRC and 161 with advanced adenomas) was 3.1% (95% confidence interval: 2.6–3.5%) and
the NNTScope was 2.3. At 75ngml
 1, the detection rate was 2.7%, the NNTScope was 2.0 and the CRC miss rate compared with
50ngml
 1 was o5% (N¼1). At 100ngml
 1, the detection rate was 2.4% and the NNTScope was o2. Compared with 50ngml
 1,
up to 200ngml
 1 CRC miss rates remained at 16% (N¼4).
CONCLUSIONS: Cutoffs below the standard 100ngml
 1 resulted in not only higher detection rates of advanced lesions but also more
colonoscopies. With sufficient capacity, 75ngml
 1 might be advised; if not, up to 200ngml
 1 CRC miss rates are acceptable
compared with the decrease in performed colonoscopies.
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Compared with the guaiac-based FOBT (G-FOBT), one of the
main advantages of some immunochemical faecal occult blood
tests (iFOBTs) is that they allow haemoglobin quantification
(Itoh et al, 1996; Castiglione et al, 2002; Guittet et al, 2007). The
semi-quantitative nature of these tests permits adjustment of
the cutoff value for the detection of colorectal cancer (CRC) in an
effort to optimise screening programmes for specific populations
and health-care practices. Changing the cutoff value can have
considerable implications on the performance of the test in a
screening population. In general, lowering the cutoff value
will increase sensitivity, but consequently decrease specificity
and vice versa. An increase in sensitivity means an increase in the
detection of patients with colorectal cancer or advanced adenomas,
but the consequential decrease in specificity results in more
persons without relevant lesions undergoing a colonoscopy (false
positives). Some studies in screening populations have been
published on changing the cutoff value of iFOBTs. However, in
these studies only a few selected cutoff values are presented, and
the complete range of possible cutoff values is not addressed
(Castiglione et al, 2002; Guittet et al, 2007; Grazzini et al, 2009).
Furthermore, colonoscopy data, verifying the presence or absence
of pathology, are usually presented for test results equal to or
above the threshold that is recommended by the manufacturer.
The two most frequently presented quantitative iFOBTs, the
OC-Sensor (Eiken Chemical) and the Magstream 1000 (Fujirebio
Diagnostics, Tokyo, Japan), were developed in Japan, where
incidence rates for CRC are lower than those in Europe (Minami
et al, 2006). Therefore, the cutoff value with optimal overall
performance may be different in Europe compared with Japan. In a
recent study including 1000 symptomatic and other high-risk
patients in Israel, cutoff values below the recommended threshold
of 100ngml
 1 were evaluated (Levi et al, 2007). The authors
concluded that the optimal cutoff value might be as low as
75ngml
 1; they also noted that the test performance in average-
risk patients in a screening population is unknown. Our aim was to
evaluate the performance and efficiency of a semi-quantitative
iFOBT in an average-risk screening population.
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Design and population
Details of study design and of most materials and methods relevant
for this study are published elsewhere (Van Rossum et al, 2008).
The study was primarily designed as a randomised controlled trial
in an average-risk screening population between 50 and 75 years of
age comparing a G-FOBT with an iFOBT. Here, we only describe
data of the semi-quantitative iFOBT, OC-Sensor, to evaluate
the performance of the iFOBT at different cutoff values in a
population-based CRC screening. The name and address of invited
subjects were randomly retrieved from municipal databases and
the iFOBT was sent directly with the screening invitation. After
2 weeks, a single written reminder was sent. For detailed infor-
mation regarding the randomisation and invitation procedure, we
refer to the earlier publication (Van Rossum et al, 2008).
iFOBT
In this study, the automated semi-quantitative OC-Sensor (Eiken
Chemical Co., Tokyo, Japan) was used. Faecal samples, preserved
in a plastic container in a liquid buffer, were processed using
an OC-Micro instrument (Eiken Chemical Co.) (Levi et al, 2007).
As threshold for positivity of the test, the manufacturer recom-
mends a cutoff value of 100ngml
 1, which has been applied in
several studies (Castiglione et al, 2002; Grazzini et al, 2004;
Sohn et al, 2005; Chiang et al, 2006; Fenocchi et al, 2006; Rubeca
et al, 2006; Van Rossum et al, 2008). The literature and data
provided by the manufacturer show that the test results of the
OC-Sensor are reliable in the range from 50 to 2000ngml
 1
(Vilkin et al, 2005), but in rare cases, the results measured can be
much higher. In a previous publication, we compared the G-FOBT
Hemoccult with the iFOBT OC-Sensor (Van Rossum et al, 2008).
In that publication, for generalisability with previous studies,
we presented data for the iFOBT with a fixed cutoff value of
100ngml
 1. However, we invited all patients with an iFOBT
result of X50ngml
 1 for colonoscopy, which data we use in this
analysis. Below 50ngml
 1, test results may become gradually more
unreliable and, to our knowledge, no data on test reliability are
available for cutoff levels below 50ngml
 1, corresponding with
±10mgg
 1 faeces (Levi et al, 2007).
Colonoscopy
Colonoscopy was offered to all iFOBT-positive patients. All
colonoscopies were carried out by experienced gastroenterologists
using conscious sedation with midazolam and fentanyl. If the
caecum could not be reached at the initial colonoscopy, the
procedure was repeated using propofol anaesthesia, or a compu-
terised tomography colonoscopy was carried out (followed by a
second colonoscopy if necessary).
During colonoscopy, all polyps and colorectal cancer were
removed if possible, and other lesions were biopsied if necessary.
Advanced adenomas were defined as adenomas with a size of
X10mm, adenomas with a villous component of X20%,
or adenomas with high-grade dysplasia. The villous component
was judged by an experienced pathologist as being either
completely villous or X20% villous or o20% villous: if in doubt,
a second opinion from another experienced GI pathologist was
requested until consensus was reached. A similar consensus
strategy was applied for high-grade dysplasia. Each CRC patient
was staged according to the American Joint Committee on Cancer
system (AJCC), also called the TNM system, which describes stages
using Roman numerals I, II, III and IV (O’Connell et al, 2004).
According to the Vienna Classification, carcinoma in situ or
intramucosal carcinoma was not classified as CRC (Schlemper
et al, 2000).
Data analysis
In population-based colorectal cancer screening, only iFOBT-
positive participants are followed-up with colonoscopy. Sensitivity
is therefore not available in our study design. Specificity can be quite
reliably estimated under the rare disease assumption as 1minus the
number of false positives relative to the total number of participants
reduced by the number of true positives, disregarding the number of
false FOBT-negative patients (negatives). (Brecht and Robra, 1987)
We used detection rates and numbers needed to scope to evaluate
the performance of iFOBT at different cutoff levels. Participants
were defined as subjects who responded to the invitation by
returning a used iFOBT. The detection rate, defined as the
percentage of participants with colorectal cancer or X1 advanced
adenomas, was used to describe the yield of the test. Positivity rate
was the percentage of positive participants and colonoscopy rate was
the percentage of positive participants adherent to colonoscopy.
Cancer miss rate was defined as the percentage of cancer patients
missed relative to the number of cancer patients at the minimal
cutoff value of 50ngml
 1 of the iFOBT. The expense of the test was
captured with the number needed to scope (NNTScope), represent-
ing the delicate ratio between true positives (all endoscoped iFOBT
positives with CRC or X1 advanced adenomas) and false positives
(no or only minor neoplasia). The NNTScope as a reciprocal of the
positive predictive value (PPV) (NNTScope¼ 1/PPV) is defined as
the number of persons undergoing a colonoscopy to detect one
person with CRC or X1 advanced adenomas.
Detection rates and NNTScope were calculated and reported
with 95% CI. In figures, detection rates and NNTScope are
presented relative to the amount of haemoglobin (ngml
 1)o na
continuous scale. Normal distribution of the iFOBT result was
achieved by logarithmic transformation. The logarithmic mean
difference in the amount of haemoglobin found in patients without
cancer or advanced adenomas compared with that in patients with
CRC or X1 advanced adenoma was analysed with logistic
regression analysis and reported with P-values. The influence of
gender and age on logarithmic mean difference was evaluated with
multivariable logistic regression analysis. Statistical analysis was
carried out with SAS system for windows, software version 8.02
(SAS Institute Inc., Cary, NC, USA).
Ethical approval and consent
The study was ethically reviewed and approved by the Dutch
Health Council (2005/03WBO, The Hague, The Netherlands). All
participants gave written informed consent for the iFOBT and, if
positive, for colonoscopy.
RESULTS
Overall, 6157 (60%) of the 10322 subjects invited to undergo the
iFOBT underwent and returned the test. Women (63%) participated
more often than men (56%) and persons o60 years of age
a little less than persons X60 years of age (59 vs 61%) (Table 1).
A positive iFOBT, i.e., a test result X50ngml
 1,w a sf o u n di n5 2 6
subjects, corresponding with a positivity rate of 8.5% (95% CI: 7.8–
9.2) of participants. The positivity rate was 6.6% for women and 10.9%
for men and, respectively, 6.4 and 10.8% for participants o60 and
X60 years of age. The age of one iFOBT positive female was unknown.
In 428 (81%) of these 526 patients, a colonoscopy was carried
out, which constituted a colonoscopy rate (positive participants
adherent to colonoscopy) of 7%. The caecum was reached in
402 patients (94%). In the 26 patients in whom the caecum could
not be reached during the first colonoscopy, a successful second
colonoscopy was carried out. In three of the stage III CRC patients,
the second colonoscopy was not completed because of the
obstructing tumour, instead a computerised tomography colono-
graphy was carried out.
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In total, 644 adenomas and 28 carcinomas were detected in
294 patients. Of the 266 patients without cancer, 161 patients had
in total 250 advanced adenomas, of which 167 (67%) were X1cm,
66 (26%) had high-grade dysplasia, 19 (8%) were completely
villous and 164 (66%) were considered to have X20% villous
aspects.
Per patient analysis
CRC was detected in 28 (7%) of the 428 patients, and in 161 (38%)
patients at least 1 advanced adenoma was detected (Table 2). Thus,
189 patients had either CRC or X1 advanced adenoma, which
amounts to 44% (95% CI: 40–49%) of the patients who underwent
colonoscopy for a positive test. Of the 161 patients with X1
advanced adenoma, 137 (85%) had one or more adenomas X1cm
and 20 patients (6%) had advanced adenomas on the basis of
villous aspects only.
iFOBT performance
The iFOBT test results ranged from 0 to 4186ngml
 1 haemo-
globin. The mean amount of haemoglobin detected in iFOBT-
positive subjects without CRC or advanced adenomas was
314ngml
 1 (95% CI: 239–388) (Table 2), which was significantly
lower than the mean amount of 785ngml
 1 (95% CI: 563–1008) in
patients with CRC and 523ngml
 1 (95% CI: 420–627) in patients
Table 1 Basic numbers and descriptive statistics of the study population invited to perform an iFOBT in population based colorectal cancer screening
Gender (%) Age group (%)
Study phase Number Statistic % Total (95% CI) Male Female o60 X60
Invited 10322
Male+female 5035+5287
Age o60+Age X60 5298+4952
Participants 6157 Participation
a 60 (59–60) 56 63 59 61
Male+female 2820+3337
Age o60+Age X60 3128+3009
iFOBT X50ngml
 1 526 Positivity
b 9 (8–9) 11 7 6 11
Male+female 306+220
Age o60+Age X60 199+326
Colonoscopy 428 Adherence
c 81 (78–82) 84 78 88 77
Male+female 257+171
Age o60+Age X60 175+252
AB
Colorectal Cancer or PPV
d 44 (39–45) 47 40 40 47
X1 Advanced Adenoma 189 NNTScope
e 2.3 (2–2.5)
Male+female 121+68
Age o60+Age X60 70+119 Detection Rate
f
Per protocol
A 3.1 (2.6–3.5) 4.3 2.0 2.2 4.0
Intention to
B screen 1.8 (2.7–3.4) 2.4 1.3 1.3 2.4
Abbreviations: CI, confidence interval; iFOBT, immunochemical faecal occult blood test; NNTScope, number needed to scope; PPV, positive predictive value.
aParticipation rate is
the number of participants relative to the number of invited persons.
bPositivity rate is the number of persons with a positive test (iFOBT X50ngml
-1) relative to the number of
participants.
cAdherence rate is the number of persons undergoing a colonoscopy relative to the number of persons with a positive test.
dPPV is the number of persons with
colorectal cancer or X1 advanced adenoma relative to the number of persons undergoing a colonoscopy.
eNNTScope is the reciprocal of the PPV (1/PPV), i.e., the number of
persons undergoing a colonoscopy relative to the number of persons with colorectal cancer or X1 advanced adenoma.
fDetection rates are calculated
Aper protocol, i.e., the
number of persons with colorectal cancer or X1 advanced adenoma relative to the number of participants and
Bintention to screen, i.e., the number of persons with colorectal
cancer or X1 advanced adenoma relative to the number of invited persons.
Table 2 Characteristics of lesions found at colonoscopy and iFOBT result (ngml
 1)
Range Percentile
iFOBT positives (X50ngml
 1) N (%) Mean (95% CI) Min Max 25th Median 75th
Without colonoscopy 98 (19) 455 (326–583) 52 2916 76 144 497
With colonoscopy 428 (81) 434 (377–492) 50 4168 80 175 482
Neither cancer nor adenomas
a 134 (31) 314 (239–388) 50 2818 76 125 347
Non-advanced Adenomas
b 105 (25) 356 (232–481) 50 4168 69 109 326
Advanced Adenomas
c 161 (38) 523 (420–627) 52 3322 100 251 582
Cancer
d 28 (7) 785 (563–1008) 59 1871 283 662 1226
Stage I or II cancer 19 (68) 652 (400–904) 59 1871 280 384 1099
Stage III or IV cancer 9 (32) 1066 (662–1470) 202 1845 622 1182 1635
Abbreviation: iFOBT, immunochemical faecal occult blood test.
aNeither cancer nor adenomas: colonoscopies without any lesions or only hyperplastic polyps, serrated adenomas
or unclassified polyps.
bNon advanced adenomas: colonoscopy with adenomas but without advanced adenomas and cancer.
cAdvanced adenomas: colonoscopies without
cancer but with adenomas X10mm in size, high grade dysplasia or a villous component X20%.
dStaging according to TNM classification: there were only 4 stage II (all stage IIa,
none stage IIb) and no stage IV patients. Therefore, stages I and II, and III and IV were combined.
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faecal sample does not follow a normal distribution; the median is
lower than the mean. The difference in the amount of haemoglobin
in the sample of patients with CRC or X1 advanced adenoma
compared with patients without significant lesions is therefore less
pronounced than the averages indicated in Table 2. By logarithmic
transformation of the test value, a normal distribution for the
(log) amount of haemoglobin was reached. Univariable logistic
regression analysis showed quantity–response relations for the
log-transformed test value and the likelihood of finding CRC
(Po0.0001), stage I or II CRC (Po0.01), stage III or IV CRC
(Po0.001) or advanced adenomas (Po0.001). In reality, only four
patients with a stage II CRC were observed, and none with stage IIb
and stage IV. Correction with logistic regression analysis for
the possible confounders, age and gender, did not change
any of the relations found, and statistical significance was robust
for all groups.
Although the results ranged from 0 to 4186ngml
 1, in Figure 1,
the detection rates for CRC and advanced adenomas are presented
for a maximum of 2000ngml
 1. Besides the overall detection rates
for CRC and advanced adenomas, separate detection rates for CRC
and advanced adenomas are presented as well. At a cutoff value of
50ngml
 1, the overall detection rate for CRC and advanced
adenomas was 3.1% (95% CI: 2.6–3.5), and the NNTScope
was 2.3 (95% CI: 2.2–2.3) (Figure 2 and Table 3). At the cutoff
value 475ngml
 1, the detection rate was 2.7% and the NNTScope
was 2, that is, in every second colonoscopy, a patient with CRC
or at least one advanced adenoma was detected. At this level one
patient with stage I cancer was excluded on comparing with the
cutoff value of 50ngml
 1. At a cutoff value of 100ngml
 1, the
overall detection rate for CRC and advanced adenomas was 2.4%
(95% CI: 2.0–2.7), and the NNTScope was 1.9 (95% CI: 1.9–2.0).
At a cutoff value of 200ngml
 1, the colonoscopy rate decreased by
450% compared with 50ngml
 1, that is, 50% less colonoscopies
had to be carried out. At this level, the detection rate for CRC
and advanced adenomas was 1.8% (95% CI: 1.5–2.2) and the
NNTScope was 1.8 (95% CI: 1.7–1.8). In the range from 100–
200ngml
 1, the cancer miss rate compared with the cutoff value
X50ngml
 1 was stable at 14% (N¼4).
According to Table 3, a decrease in the cutoff value from
100ngml
 1 to 50ngml
 1 resulted in increasing detection rates of
advanced lesions from 2.4 to 3.1%, but at the cost of more colono-
scopies that needed to be carried out, from 4.5 to 7%, and higher
rates of colonoscopies without significant lesions. Increasing
the cutoff value from 100 to 200ngml
 1 decreases the detection
rate for advanced adenomas substantially from 2.4 to 1.8%,
not affecting the detection rate for cancer. The colonoscopy rate is
reduced to 50% by using a cutoff value of 200ngml
 1 compared
with 50ngml
 1 (3.2 vs 7%). The cancer miss rate at 200ngml
 1
compared with 50ngml
 1 is 14%.
In Figure 3A–D, the relation between detection rates and
NNTScope for subjects o60 years and X60 years, and for men and
women, is presented.
DISCUSSION
We evaluated the performance and efficiency of a semi-quantita-
tive iFOBT, the OC-Sensor, in an average-risk screening popula-
tion. We presented detection rates and numbers needed to scope
over the complete effective range of the test, and we have shown
that, below the threshold of 100ngml
 1 recommended by the
manufacturer of the test, even at the lowest functional value of
50ngml
 1 tested, the performance could be considered acceptable.
At the 50ngml
 1 level, both cancer and advanced adenomas were
detected at the cost of significantly more colonoscopies. At higher
cutoff levels than the standard 100ngml
 1, significantly less
colonoscopies have to be carried out; moreover, compared with
100ngml
 1, the cancer miss rate was nil but the miss rate of
advanced adenomas was substantial.
In a previous publication, we demonstrated that the performance
of the G-FOBT, Hemoccult-II, is lower than the performance of
ng Haemoglobin per ml sample solution
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Figure 1 The detection rate (%) for colorectal cancer and advanced adenomas for the operative range of the immunochemical faecal occult blood test
(iFOBT) (50–2000ngml
 1). Overall detection rate of colorectal cancer and advanced adenomas (O), subgroup detection rates of colorectal cancer (C) and
advanced adenomas (A) (adenomas X10mm, adenomas with high-grade dysplasia or adenomas with a villous component X20%).
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sthe iFOBT, OC-Sensor, at the standard cutoff value of 100ngml
 1
(Van Rossum et al, 2008). The PPV for CRC and advanced
adenomas of the G-FOBT was 55.3%, which was reached with the
iFOBT at a cutoff of 130ngml
 1. At this cutoff, the NNTScope
of iFOBT was equal to that of G-FOBT, but the detection rate
for CRC was more than 2.5 times higher for iFOBT compared with
that for G-FOBT, and for advanced adenomas, this was almost
twice as high.
The quantitative aspect of the iFOBT allows to adjust the cutoff
value to a screening programme and can be based on aspects
such as the intended detection rate, population-related factors (e.g.,
prevalence of CRC, participation rates) and political issues such as
colonoscopy capacity. The cutoff value with the most optimal
performance of the iFOBT may differ in various populations and
may change over time, because the performance is dependent on
the prevalence of CRC and advanced adenomas. Therefore, the data
Table 3 The performance characteristics of the iFOBT, OC-Sensor, at different cutoff levels
Cutoff values (ngml
 1)
50 75 100 125 150 175 200 225
Positives adherent to colonoscopy
a (N) 428 336 280 248 234 215 198 187
Colonoscopy rate
b (%) 7.0% 5.5% 4.5% 4.0% 3.8% 3.5% 3.2% 3.0%
Number of lesions (n)
Colorectal cancer 28 27 24 24 24 24 24 23
CRC+advanced adenomas 189 163 145 136 131 121 113 109
Detection rate
c (%)
Colorectal cancer 0.45% 0.44% 0.39% 0.39% 0.39% 0.39% 0.39% 0.37%
Confidence interval (95% CI) 0.3–0.6% 0.3–0.6% 0.2–0.6% 0.2–0.6% 0.2–0.6% 0.2–0.6% 0.2–0.6% 0.2–0.5%
CRC+advanced adenomas 3.1% 2.6% 2.4% 2.2% 2.1% 2.0% 1.8% 1.8%
Confidence interval (95% CI) 2.6–3.5% 2.3–3.1% 2–2.7% 1.8–2.6% 1.8–2.5% 1.6–2.3% 1.5–2.2% 1.4–2.1%
Number Needed To Scope
d (N/n)
Colorectal cancer 15.3 12.4 11.7 10.3 9.8 9.0 8.3 8.1
Confidence interval (95% CI) 11.3–23.8 9.1–19.5 8.4–18.9 7.5–16.7 7.1–15.7 6.5–14.4 6–13.2 5.9–13.2
CRC+advanced adenomas 2.3 2.1 1.9 1.8 1.8 1.8 1.8 1.7
Confidence interval (95% CI) 2.6–2.5 1.9–2.3 1.7–2.2 1.6–2.1 1.6–2 1.6–2 1.6–2 1.5–2
Specificity
e
CRC+advanced adenomas 96.0% 97.1% 97.8% 98.1 98.3 98.4 98.6 98.7
Confidence interval (95% CI) 95.5–96.5% 96.7–97.5% 97.4–98.1% 97.8–98.5% 98.0–98.6% 98.1–98.8% 98.3–98.9% 98.4–99.0%
CRC miss rate
f (%) N.A. 3.6% 14.3% 14.3% 14.3% 14.3% 14.3% 17.9%
Confidence interval (95% CI) N.A.  3.3–10.4% 1.3–27.2% 1.3–27.2% 1.3–27.2% 1.3–27.2% 1.3–27.2% 3.7–32%
Abbreviations: CI, confidence interval; CRC, colorectal cancer; iFOBT, immunochemical faecal occult blood test.
aPostives adherent to colonoscopy¼patients with a positive
iFOBT who underwent a colonoscopy.
bColonoscopy rate¼percentage of participants with a positive iFOBT who underwent a colonoscopy.
cDetection rate¼percentage of
participants with lesions of reference.
dNumber Needed To Scope¼the number of patients to find one extra patient with lesions of reference.
eSpecificity was calculated under
the rare disease assumption (Brecht and Robra, 1987).
fCRC miss rate¼the percentage of the colorectal cancer patients at that cutoff relative to the colorectal cancer patients at
the minimal 50ngml
 1 cutoff.
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Figure 2 The overall detection rate and number needed to scope for cancer and X1 advanced adenomas focused on the range between 50 and
200ngml
 1. Left axis: detection rate for colorectal cancer and advanced adenomas (-K-) Right axis: number needed to scope for colorectal cancer and
advanced adenomas (-&-) (by definition X1.0).
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without considering these variables. However, we do think extra-
polation of results will be quite appropriate for most European
countries, as the prevalence of CRC and the capacity of adequate
health care are comparable (Regula et al, 2006; Segnan et al, 2007).
With regard to colonoscopy capacity, the colonoscopy rate of
7% at the lowest cutoff value of 50ngml
 1 could be considered
acceptable if compared with that of countries with primary
colonoscopy screening, Moreover, in case of a colonoscopy
because of a positive iFOBT, the positive predictive value for
ng Haemoglobin per ml sample solution
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Figure 3 The detection rate (%) and number needed to scope for colorectal cancer and X1 advanced adenomas focused on the range between 50 and
200ngml
 1 for males (A)( N¼257), for females (B)( N¼171), patients o60 years of age (C)( N¼252) and for patients X60 years of age (D)( N¼175).
Left axis: detection rate for colorectal cancer and advanced adenomas (-K-). Right axis: number needed to scope (NNTScope) for colorectal cancer and
advanced adenomas (-&-) (by definition X1.0).
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sadvanced lesions will be substantially higher than in persons
undergoing primary colonoscopy screening.
Previous studies published regarding semi-quantitative
iFOBTs in screening populations did not address the true
continuous nature of these tests (Castiglione et al, 2002; Guittet
et al, 2007). Furthermore, these studies did not present colono-
scopy results below the threshold recommended by the manu-
facturer. In a recent study on 1000 symptomatic and other
high-risk patients in Israel with the same OC-Sensor test from
Eiken Chemical, cutoff values below the recommended threshold
were evaluated (Levi et al, 2007). The results of this study are
comparable with our results, and the authors suggested that a
cutoff level of 75ngml
 1 would probably achieve optimal results,
acknowledging the fact that population-based screening data are
needed for confirmation.
A limitation of our study was that we only have data for one
sample of iFOBT. In the previously mentioned study, 1000
symptomatic and other high-risk patients in Israel were asked to
undergo three separate sample tests (Levi et al, 2007). The authors
observed an increased sensitivity for more than one sample,
although the difference between two and three samples was not
significant and the specificity decreased when more samples were
used. It is conceivable that a screening strategy with two samples
results in a different optimal cutoff value when compared with one
sample screening. However, an increase in sensitivity and therefore
detection rate by two tests could be matched by a decrease in
participation rate, resulting in a decrease in detection rate
according to an intention-to-screen analysis.
It is unavoidable in population-based screening studies with a
two tier model (that is, colonoscopy only under the condition of a
positive pretest) to not offer a colonoscopy to iFOBT negatives;
therefore, sensitivity of the iFOBT could not be calculated in this
study. However, the sensitivity of the iFOBT could possibly be
estimated for the purposes of cost-effectiveness studies, provided
extensive sensitivity analyses are carried out for incidence and
prevalence, because incidence and prevalence of colorectal cancer
seem quite similar in most European countries (Regula et al, 2006;
Ferlay et al, 2007; Segnan et al, 2007; Hundt et al, 2009).
Of the participants with a positive iFOBT, 19% did not adhere to
the colonoscopy. Similar percentages have been observed in other
population-based screening studies (Faivre et al, 2004). While
designing our study (using municipal databases), we were unable
to carry out a pre-selection according to eligibility. Therefore,
this percentage consists of those individuals who refused to
undergo colonoscopy, and also individuals who were excluded for
colonoscopy because of, e.g., severe co-morbidity or recent
colonoscopy. As we conducted an implementation study, we did
not exclude these patients from the 19% who were not adherent to
colonoscopy.
The villous component for advanced adenoma status can be
difficult to evaluate, especially if the level is on the predefined limit
of 20%. However, the percentage of patients with a colonoscopy
with only a villous component as the criterion for advanced
adenoma status was 6% of all patients. Of all patients with
advanced adenomas, 85% had at least an adenoma X10mm in
size. Even if all 20 patients with only a villous component had been
excluded from the group with advanced adenomas, our conclu-
sions would have remained identical.
Advanced adenomas and CRC were found more often in men
than in women, and advanced adenomas and CRC were also more
often detected in older persons. This is in line with other studies
(Manus et al, 1997; Betes et al, 2003; Sedjo et al, 2007). Thus, the
diagnostic yield increases with age and male gender. We showed
that for gender and different age groups, other optimal cutoff
values might be valid, but with the present data, we were unable to
verify the validity of any specific recommendations. It might be
interesting to investigate the possibility, as well as the accept-
ability, of age- and gender-specific cutoff values.
In conclusion: This study presents evidence that, below the
standard threshold of 100ngml
 1, which is recommended by the
manufacturer of the iFOBT OC-Sensor, acceptable performance
could be achieved even at the lowest functional value of 50ngml
 1.
Substantially higher detection rates for colorectal cancer and for
advanced adenomas correspond with increasing numbers needed
to be scoped. However, the positivity rate and the resulting
number of colonoscopies to be carried out are relatively high
compared with higher cutoff values (100–200ngml
 1). We
propose that a cutoff value below 100ngml
 1 would be feasible
and acceptable in screening programmes in many Western
European countries, assuming resources and colonoscopy capacity
are sufficient. However, when resources and colonoscopy capacity
are not sufficient, cutoff values above 100ngml
 1 (up to
200ngml
 1) will result in a relatively limited miss rate for
colorectal cancer and a lower but still quite high detection rate of
advanced adenomas at the expense of a decrease in the total
number of colonoscopies to be carried out. Policy makers will
determine the optimal cutoff value on the basis of a largely
arbitrary balance between the acceptability of missing cancer and
the possibility and acceptability of assigning essential resources. In
the Netherlands, there is indication that a cutoff of 75ngml
 1 is
considered for implementation in national screening.
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